Type 1 Diabetes Clinical Trial
Official title:
Impact of Type 1 Diabetes and Glycated Haemoglobin Levels on Oxygen Delivery and Release to Active Muscle During Exercise and on Muscle Oxidation Capacity - Possible Impact on Aerobic Fitness
Most of the studies concerning aerobic fitness in Type 1 diabetic patients noted a relationship between impaired aerobic fitness and high glycated haemoglobin (HbA1c) levels, reflecting poor long term glycaemic control. To explain this relationship, the indirect effect of chronically high blood glucose levels on cardiovascular complications - and hence on exercise cardiovascular adaptations - are often mentioned. However, one could wonder if HbA1c could also have a direct impact on aerobic fitness patients with Type 1 diabetes. Haemoglobin glycation may increase its O2 affinity, thus limiting the O2 availability at the muscular level and impairing maximal aerobic power. Moreover, chronic hyperglycaemia might have deleterious effect on muscle mitochondrial capacity to use O2. The aim of this study is to assess the effect of Type 1 diabetes and of HbA1c level on muscular oxygen delivery and use and hence on aerobic fitness.
The current study aims at assessing the impact of Type 1 diabetes and HbA1c on muscle oxygen
delivery and on muscle mitochondrial capacity. Our hypothesis is that these both steps of
the oxygen cascade might be involved in the aerobic fitness impairment usually observed in
poor-controlled patients.
Adults with Type 1 diabetes, aged 18-40 years, without microvascular and macrovascular
diabetic complications, will be recruited among patients that regularly attend the unit of
diabetology of the University Hospital of Lille and the regional hospital of Roubaix. They
will be separated into 2 groups according to their glycaemic control at entrance in the
study (HbA1c < 7%, HbA1c > 8%). Subsequently, two healthy control groups (checked by an
OGTT) will be selected to strictly match the patients with Type 1 diabetes (age, sex, BMI,
number of hours of physical activity per week, tobacco smoking). This is a cross-sectional
study including 4 groups.
On their first visit, after the determination of HbA1c, all the subjects will perform at
rest a DLCO/DLNO. Then they will realise an incremental exercise test to exhaustion on an
electromagnetic cycle ergometer. Non-invasive measures will be performed throughout the
exercise test, including gas exchange parameters (and maximal oxygen uptake), muscular and
brain oxygenation (Near Infra Red Spectroscopy at vastus lateralis muscle and at prefrontal
cortex). A blood sample from an arterialised ear-lobe will be taken at rest and exhaustion
to determine O2 haemoglobin saturation, arterial partial pressure in O2 and CO2, haemoglobin
concentration, hematocrit, and bicarbonates. Blood, from a catheter in a superficial cubital
vein, will also be taken at rest, at a precise time during the exercise and immediately
after the exercise to measure potential of hydrogen, bicarbonates, haemoglobin
concentration, hematocrit, erythrocyte 2,3-diphosphoglycerate, and other blood markers of
metabolic and hormonal adaptations to exercise. The subjects will also fill in
questionnaires.
On a second visit, in a fasting state, the subjects will have a muscle biopsy at vastus
lateralis using a specific needle (less than 150mg) in order to assess mitochondrial
respiration capacity and endocannabinoid system activity. A venous blood sampling will allow
analysing other health markers (lipid profile, insulin resistance...).
On another visit, the subjects will have a measure of body composition by Dual energy X-ray
Absorptiometry and skinfold thickness.
They will also wear an accelerometer over one week and fill in a diet questionnaire over 3
days.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |